Compare Organon & Co. Common Stock (OGN) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PulteGroup, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PulteGroup, Inc. trades at $110.09 (market cap $21.25B). The key difference: PulteGroup, Inc. is far larger — about 5.9× Organon & Co. Common Stock's market cap, and PulteGroup, Inc. pays the higher dividend (0.93%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PulteGroup, Inc. for 91 Days on average.
| OGN | PHM | |
|---|---|---|
Market Cap | $3.62B | $21.25B |
Volume | 2,892,999 | 1,784,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $142.56 |
52-Week Low | $5.70 | $109.35 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $11.04B | $21.67B |
Dividend Yield | 0.58% | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PulteGroup (PHM) trades at $109.35, down 1.61% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though it beat expectations in Q2 2026. Fundamentally, the company maintains solid profitability with 11.62% net margin and attractive valuation at 11.4 P/E. Analyst consensus remains mixed with 45% buy ratings but a $139.64 price target suggesting 28% upside potential from current levels.
PHM presents a value opportunity with strong cash flow generation and dividend yield, though near-term headwinds from rising interest rates and housing affordability concerns create volatility. The stock's current discount to analyst targets and reasonable valuation metrics support long-term potential, but investors should monitor Q3 2026 earnings on October 22 for confirmation of business resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
